Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO.
Purity:
>95%
CAS Number:
[1607793-29-2]
Target:
RAAS|||VEGFR
* VAT and and shipping costs not included. Errors and price changes excepted
